MBX Biosciences Inc.

06/06/2025 | Press release | Distributed by Public on 06/06/2025 05:59

Management Change/Compensation, Proxy Results (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2025, MBX Biosciences, Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). As further described under Item 5.07 below, the Company's stockholders approved the election of two Class I directors to serve for a three-year term ending at the annual meeting of stockholders to be held in 2028. Also effective as of June 5, 2025 was the departure of Carl L. Gordon, Ph.D., CFA from the Company's board of directors. Dr. Gordon served on the Company's board of directors since July 2020, and his term as a director concluded at the 2025 Annual Meeting.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on June 5, 2025. As of April 11, 2025, the record date for the Annual Meeting, there were 33,424,371 shares outstanding shares of the Company's common stock. The Company's stockholders voted on the following matters, which are described in detail in the Proxy Statement: (i) to elect two Class I director nominees, Tiba Aynechi, Ph.D. and P. Kent Hawryluk, to the Company's Board of Directors, each to hold office until the Company's 2028 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal ("Proposal 1") and (ii) to ratify the appointment of the Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 ("Proposal 2").

The Company's stockholders approved the Class I director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company's stockholders voted for Class I directors as follows:

Class I Director Nominee

For

Withhold

Broker Non-Votes

Tiba Aynechi, Ph.D.

24,328,105

1,662,096

1,788,025

P. Kent Hawrlyuk

24,412,560

1,577,641

1,788,025

The Company's stockholders approved Proposal 2 to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes cast at the Annual Meeting were as follows:

For

Against

Abstain

Broker Non-Votes

27,773,930

3,467

829

-

MBX Biosciences Inc. published this content on June 06, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 06, 2025 at 12:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io